Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

• Status: Terminated
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborator: Dr. Jeffrey Thomas Stroke Shield Foundation
• Treatments: Deferoxamine

Criteria

Inclusion Criteria:

• diagnosis of spontaneous SAH

• impaired cerebral autoregulation on day 2-4 post SAH

Exclusion Criteria:

• traumatic SAH

• other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations

• pregnancy

• severe renal disease or anuria